Kif2a和淋巴结转移密度对乳腺癌的预后价值研究

Prognostic value of Kif2a and lymph node metastasis density in breast cancer

摘要:

目的探讨驱动蛋白家族成员2a（Kif2a）和淋巴结转移密度（ND）对乳腺癌的临床病理学意义及预后评估。方法采用免疫组织化学法检测116例乳腺癌组织中Kif2a蛋白的表达，按ND分为ND=0 组、ND≤40%组和ND>40%组，分析Kif2a 蛋白的表达、ND 与乳腺癌患者的临床病理因素（年龄、肿瘤部位、肿瘤大小、组织学类型、TNM 分期）、内分泌表型（雌激素受体、孕激素受体）、HER-2 及预后的关系。采用Kaplan-Meier生存曲线分析，评价Kif2a 蛋白表达、ND与乳腺癌患者的预后。结果乳腺癌组织中Kif2a 蛋白的表达、ND均 与患者TNM 分期及HER-2 的阳性表达呈正相关（Rs=0.251、0.489、0.536 和0.245，P =0.007、0.000、0.000 和0.008），与其他临床病理因素无关（P >0.05）。Kif2a 的表达与ND呈正相关（Rs＝0.484，P =0.000）。生存曲线分析结果显示，Kif2a 蛋白表达越强、ND越高，无瘤生存时间越短（P <0.05）。结论驱动蛋白Kif2a、ND 可能是乳腺癌患者预后的独立因素，其对判断乳腺癌患者的预后具有一定价值。

Abstract:

Objective To investigate the clinicopathological significance and prognosis of kinesin family member 2a (Kif2a) expression and lymph node metastasis density (ND) in breast cancer. Methods The expression of Kif2a protein in 116 cases of breast cancer was detected by immunohistochemistry. According to the results of ND the patients were divided into ND = 0 group, ND ≤40% group and ND > 40% group. Relations of of Kif2a expression and ND with the clinicopathological factors (age, tumor location, tumor size,histological type and TNM stage), endocrine phenotypes (ER, PR), HER-2 and prognosis in breast cancer patients were analysed. Kaplan-Meier survival curve was applied to evaluate the expression of Kif2a protein,ND and prognosis of the patients with breast cancer. Results Both Kif2a protein expression and ND were positively correlated with TNM stage and positive HER-2 expression in breast cancer (Rs = 0.251, 0.489, 0.536 and 0.245;P = 0.007, 0.000, 0.000 and 0.008), but not correlated with other clinicopathological factors (P >0.05). The expression of Kif2a was positively correlated with ND (Rs = 0.484,P = 0.000). Survival curve analysis showed that the higher the expression of Kif2a protein, the higher the ND, the shorter the tumor-free survival time (P < 0.05). Conclusions Kif2a and ND may be independent prognostic factors in patients with breast cancer, and may have certain value in predicting the prognosis of patients with breast cancer.